Last reviewed July 2021
Currently, there are other dual GIPR/GLP-1R agonists available, such as GLP-1R/GR (glucagon receptor), GLP-1R/AR (amylin receptor), and GLP-1R/NPYR (peptide YY binds to neuropeptide Y receptors) [36, 115] and even triple agonists that can activate GIPR to treat obesity and T2DM
This section will briefly review what we know about the current safety data of GLP-1 and GLP-1/GIP agonists, and factors that may promote long term clinical use of these agents in obesity
Overdosing causes unnecessary side effects and potential health risks
For smoother blood concentration and reduced peak-related side effects, some users opt to split the dose into bi-weekly injections (every 3.5 days)
The Compounding Controversy Pharma isnt satisfied with these answers, and theyre worried about liability and cannibalization stemming from counterfeit or black market usage of off-label GLP-1s